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This study was to create a long-term rabbit model of diabetes mellitus for medical studies of up to one year or longer and to
evaluate the eﬀects of chronic hyperglycemia on damage of major organs. A single dose of alloxan monohydrate (100mg/kg) was
given intravenously to 20 young New Zealand White rabbits. Another 12 age-matched normal rabbits were used as controls.
Hyperglycemia developed within 48 hours after treatment with alloxan. Insulin was given daily after diabetes developed. All
animals gained some body weight, but the gain was much less than the age-matched nondiabetic rabbits. Hyperlipidemia, higher
blood urea nitrogen and creatinine were found in the diabetic animals. Histologically, the pancreas showed marked beta cell
damage. The kidneys showed signiﬁcantly thickened aﬀerent glomerular arterioles with narrowed lumens along with glomerular
atrophy. Lipid accumulation in the cytoplasm of hepatocytes appeared as vacuoles. Full-thickness skin wound healing was delayed.
In summary, with careful management, alloxan-induced diabetic rabbits can be maintained for one year or longer in reasonably
good health for diabetic studies.
1.Introduction
Diabetes Mellitus is one of the leading causes of death,
illness, and economic loss in the United States [1]. Not
surprisingly, an extensive amount of research is ongoing
which is directed at the cause, diagnosis, and treatment of
this crippling disorder [2]. Animal experimentation has a
long history in the ﬁeld of diabetes research. To induce
diabetes in animals, toxic chemicals such as streptozotocin
[3]a n da l l o x a n[ 4] are popularly used. Transgenic rodent
models of diabetes are gaining popularity. A major criticism
of using rodents is that, due to their short life span, they
may not develop the clinical complications seen in humans
that have been diabetic for a number of years. Cats, dogs,
swine, and nonhuman primates are occasionally used [5].
Rabbits are a potentially overlooked, manageable species for
chronic diabetes experiments. They are considered lower on
the phylogenetic scale than cats, dogs, swine, and nonhuman
primates, and they have an average life-span of 5–8 years
which is signiﬁcantly longer than rodents.
Studieshavedemonstratedthatrabbitspossesscharacter-
istics desirable in a laboratory animal model including con-
venient size, longer life span, strain speciﬁc, have good tem-
peraments, are easily handled and are relatively inexpensive
[6]. We searched PubMed and in the past decade more than
1000 studies have been conducted using rabbits as a model
of diabetes [7]. However, most of these experiments used
rabbits that were diabetic for only several weeks to 2 months
[8]. Studies of these durations have severely limited diabetic
research capabilities as many complications of diabetes
require years to develop [5]. In this study, we created a long-
termrabbitmodeloftype1diabetesmellituswithreasonably
good health for experimental usage for one year or longer.
This paper reports our management strategies and physical,
biochemical, and histological ﬁndings of these rabbits.
2. Methods
The study was conducted in accordance with the National
Institutes of Health guidelines for the care and use of2 Experimental Diabetes Research
animals in research, and the protocol was approved by
the Institutional Animal Care and Use Committee of the
University of Louisville, an AAALAC accredited program.
A total of 32 young (8–10 weeks, 2.13 ± 0.24kg), male
New Zealand white rabbits, Oryctolagus cuniculus (Myrtle’s
Rabbitry, Thompson Station, TN) were divided into two
groups. The ﬁrst group consisted of 20 animals with
chemically induced type 1 diabetes mellitus; the second
group consisted of 12 age-matched control (orthoglycemic)
animals. Animals were singly housed in stainless steel caging
with slotted ﬂoors (40 × 60 × 80cm) in a temperature
(16–22◦C) and humidity (30–70%) controlled room on a
12:12 hour light:dark cycle. Cage pans were cleaned three
times per week and cage racks were cleaned once weekly.
Laboratory Rabbit Diet HF 5326 (LabDiet, PMI Nutrition
International) supplemented with certiﬁed timothy hay
cubes (Bio-Serv, Frenchtown, NJ) and ﬁltered tap water
was provided ad libitum through an automated watering
system from arrival throughout the end of the study.
Environmental enrichment consisted of a variety of fresh
vegetables at least once weekly, dumbbells and stainless steel
rattles (Bio-Serv, Frenchtown, NJ). Vendor microbiological
monitoring health reports indicated that the rabbits were
serologically negative for the following pathogens: CAR
Bacillus, Encephalitozoon cuniculi, Pasteurella multocida,
Treponema cuniculi, and Oral Papilloma Virus. The rabbits
were also negative for Bordetella bronchiseptica, Salmonella,
Klebsiella, Citrobacter, and Clostridium piliformis. Animals
were free of internal and external parasites. Before any
experimental manipulations were initiated the rabbits were
allowed to acclimate for at least 7 days.
2.1. Induction and Management of Diabetes Mellitus. Rabbits
were weighed weekly throughout the study and the weights
were recorded. For the alloxan injection, rabbits were lightly
anesthetized with ketamine hydrochloride 30mg/kg and
xylazine 3mg/kg (IM). Artiﬁcial tears ointment (Butler
Animal Health Supply, Dublin, OH) was applied to the
surfaceofbotheyestopreventdrying.Bodytemperaturewas
maintained with a warm water circulating blanket (Gaymar
TP u m p ,G a y m a rI n d u s t r i e sI n c . ,O r c h a r dP a r k ,N Y ) .H e a r t
rate, respiratory rate, body temperature, and SpO2 were
monitored while the animals were under anesthesia and
through recovery. Alloxan monohydrate (Sigma Aldrich
Chemical, Saint Louis, MO, USA) was dissolved in sterile
normal saline to achieve a concentration of 5% (W/V), and
100mg/kg was immediately administered intravenously via
the marginal ear vein over a period of 2 minutes with a
25 gauge butterﬂy catheter. The rabbits were allowed to
recover from anesthesia. To avoid mortalities during the
hypoglycemic phase, alloxan was administrated to nonfasted
animals, and food and water were oﬀered to animals
immediately upon recovery after anesthesia. At 4, 8, and
12 hours following alloxan injection, 10ml of glucose (5%
W/V)wasadministeredsubcutaneously,andanoralsolution
of 20% glucose in tap water was provided via water bottle
ad libitum for 1-2 days after conﬁrmation of hypoglycemia
(less than 70mg/dl) to prevent hypoglycemic shock. During
this period access to the automated watering system was
restricted to encourage intake of the oral glucose solution.
Rabbits whose blood glucose levels remained <300mg/dl
for more than one week following the initial injection of
alloxan received a second dose of alloxan (100mg/kg IV) to
maintain a blood glucose level >300mg/dl for the duration
of the study. Blood glucose concentration was measured
1-2 times per day using a blood glucose meter (LifeSpan,
Inc. Milpitas CA) for the ﬁrst 4 weeks and once weekly
thereafter in the morning. If morning blood glucose levels
(BGL) were higher than 350mg/dl, regular insulin (Novolin-
R, Novo Nordisk Pharmaceuticals Inc. Princeton, NJ) was
administeredsubcutaneously(SC)oncedailywitha30gauge
needle. The insulin dose was adjusted according to the
blood glucose level for the individual rabbit based on the
following: (1) BGL < 400mg/dl received 1U/kg, (2) BGL
= 400–500mg/dl received 2U/kg, (3) BGL = 500–600mg/dl
received 3U/kg, and (4) BGL > 600mg/dl received 4U/kg.)
In animals with BG levels > 500mg/dl, a second insulin
injection (half of the morning dose) was administered in the
late afternoon. Blood and urine samples were collected for
biochemical analysis weekly for two months then monthly
until the end of experiment. Blood was collected from the
central auricular artery with a 25 gauge needle. For urine
collection, clean cage pans were placed under the cages
without liners, and urine was collected for 24 hours.
2.2. Determination of Insulin Dose. Due to individual vari-
ation and sensitivity to insulin, the insulin dose for each
rabbitwasdeterminedshortlyaftertheinductionofdiabetes.
A blood glucose curve was performed by administering a
test dose of insulin (based on the aforementioned dosing
rate) after measuring the blood glucose concentration in the
morning. Blood glucose concentration was then measured
every hour for 10 hours when it was clear that blood glucose
levels were continuing to rise to obtain a glucose curve. If the
lowest blood glucose was less than 50mg/dl or higher than
200mg/dl, a new glucose curve was obtained the next day
by decreasing or increasing the insulin dosage until the best
dose was obtained. The ﬁnal insulin dose was determined
when a glucose curve was obtained where the peak BGL was
>350mg/dl and the trough BGL was ≥50mg/dl. If rabbits
developed symptoms of illness (such as a loss of appetite,
ptyalism, or severe weight loss) during the experiment, a
new BG curve was obtained and a new insulin dose was
implemented.
2.3. Pinna Wound Healing Model. To evaluate the eﬀect
of long-term diabetes on wound healing, we created full
thickness skin wounds on the ventral surface of the pin-
nae in both diabetic and nondiabetic age-matched rabbit
groups at 2 weeks and one year using a minimally invasive
surgical technique [9, 10]. Brieﬂy, one hour before surgery,
rabbits were injected subcutaneously with buprenorphine
(0.03mg/kg), and were anesthetized and monitored as
described above. Under aseptic conditions, four circular full-
thickness wounds were created on each ear with a 6-mm
stainless steel punch. Prior to recovery a 25μg/hr Fentanyl
transdermal patch (Duragesic, Ortho-McNeil, Raritan, NJ),
was applied to the skin over the shoulders for analgesia.Experimental Diabetes Research 3
Sterile normal saline was used to dress all wounds. The
woundswerethencoveredwithTegaderm(3M,St.Paul,MN,
USA). Wound dressings were changed and digital photos
were taken daily until the wounds were closed. Wounds were
considered closed when they were totally reepithelialized [9,
10] and further conﬁrmed by histology and morphometric
analysis [11, 12] using Nikon Eclipse Ti microscope and
Nikon Element software.
2.4. Biochemistry Analysis. Plasma was obtained by cen-
trifugation of blood samples at 2500g for 20min at 4◦C,
and was stored at −20◦C until analysis. The activity of
plasma lactate dehydrogenase (LDH), creatine kinase (CK),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), total protein, cholesterol, triglycerides (TG), blood
urea nitrogen (BUN), and creatinine was assayed using a
Roche Cobas Mira Plus chemistry analyzer (Roche Diag-
nostic System, Inc, Branchburg, NJ). Beta-hydroxybutyrate
(BHBA) was also analyzed in some samples. All regents
used in the analysis were purchased from CATACHEM
(Bridgeport, CT, USA).
Urine samples were collected for 24 hours as previously
described. The volume of urine collected was recorded, and
its protein content was analyzed with a Roche Cobas Mira
Plus chemistry analyzer. Ketones were analyzed by IDEXX
VetLab (One IDEXX Drive, Westbrook, ME, USA).
2.5. Preparation of Tissue Samples. At the end of 12 months,
rabbits were euthanatized with 100mg/kg pentobarbital
(IV). Tissue samples were taken from the pancreas, liver,
kidney,aorta,andpinnaforhistologicalstudies.Thesamples
were ﬁxed in 4% buﬀered formaldehyde and embedded
in paraﬃn. Six μm slices were made from the paraﬃn
blocks which were stained with hematoxylin and eosin and
evaluated for histological changes.
2.6. Statistical Analysis. Results are reported as mean and
standard deviation (SD). Student’s t-test was used to com-
pare the two groups and ANOVA was used for repeated
longitudinal measurements with commercially available sta-
tistical software (GraphPad Software, Inc. San Diego, CA). A
P value of <.05 was considered signiﬁcant.
3. Results
3.1. Animals. Of the 20 alloxan-treated rabbits, two died at
6 and 9 months secondary to renal failure. Four animals
were used for a 2-week wound healing study, and 6 of the
animals were used for a one-year wound healing study. The
remaining 8 rabbits are still alive after 12 months.
3.2. Alloxan Dose and Hyperglycemia. Baseline nonfasting
blood glucose levels were normal for all animals (124 ±
17mg/dl). After the administration of alloxan there was a
characteristic response in blood glucose level [4]. In the
ﬁrst 2 hours, blood glucose increased. The second phase,
which was observed approximately 6 hours following alloxan
injection, was a hypoglycemic phase which persisted for 24–
48 hours. By that time the animals were alert, active, eating
and drinking glucose water unassisted. It was determined
that 24 hour continuous observation was not necessary.
During our study, the blood glucose of some rabbits
decreased to life threatening levels (less than 50mg/dl).
However, no animals died in the hypoglycemic phase of
this study. The third phase was persistent hyperglycemia. Of
the 20 alloxan-treated rabbits, blood glucose levels generally
increased up to 300mg/dl within 48 hours of receiving
alloxan. After two weeks, the diabetic animals were divided
into three groups according to their morning blood glucose
levels: 300–400mg/dl (n = 7), mild diabetic group; 401–
500mg/dl (n = 7), moderately severe diabetic group;
greater than 501mg/dl (n = 6), severe diabetic group.
We found that animals in the mild group exhibited body
weight increases rather quickly however their blood glucose
levels decreased below 300mg/dl 3–8 weeks after the ﬁrst
injection of alloxan, and a second injection of alloxan was
required. Twelve animals required a second injection of
alloxan to maintain persistent hyperglycemia (>300mg/dl).
An interesting ﬁnding is that the second injection of alloxan
did not induce the characteristic hypoglycemic that was
observed following the initial dose of alloxan. Therefore
animals that received a second dose of alloxan did not
require glucose supplementation. All animals that received
a second dose of alloxan survived until the end of the
experiment.
3.3. Insulin Dose and Glucose Concentration. In most of the
rabbits, blood glucose concentrations followed a relatively
predictable pattern. After insulin administration, blood glu-
cosereachedatrough(70–150mg/dl)2hoursafterinjection.
By four hours after insulin BG levels began to rise and
were >300mg/dl within 6 hours and peaked the following
morning before the next insulin injection. The mean time
that rabbits were maintained in a hyperglycemic state was 16
hours. The mean time that rabbits were normoglycemic was
8h o u r sp e rd a y .
3.4. Body Weight. Baseline mean body weight of the rabbits
was 2.13 ± 0.24kg. Food intake was not measured in this
study, however fecal output was assessed by husbandry
staﬀ daily and any decrease from normal production was
brought to the attention of the study director and a clinical
veterinarian. Although the blood glucose levels were very
high, there was a tendency toward weight gain in all of the
diabetic rabbits. There appeared to be a negative relationship
between the highest blood glucose levels observed and body
weight gain. At the end of 12 months, their body weights
ranged from 3.12 to 4.18kg, while the body weights of the
age-matched nondiabetic rabbits ranged from 4.86–5.96kg.
The body weight increase of the diabetic rabbits was signif-
icantly lower than that of age-matched nondiabetic rabbits
(P< . 05).
3.5. Polyuria and Proteinuria. Both Polyuria and Proteinuria
are characteristics of diabetes. Following diabetes induction
in the rabbits, there were signiﬁcant increases in urine
volume (P = .0019, Figure 1(a)) and urine protein (P =
.0004, Figure 1(b)) compared with the baseline.4 Experimental Diabetes Research
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Figure 1: Changes in renal function. (a) and (b) there was a signiﬁcant increase in urine and urine protein in diabetic rabbits as compared
with baseline; (c) and (d) there was a statistically signiﬁcant diﬀerence in blood urea nitrogen (BUN) and serum creatinine levels between
the diabetic and age-matched nondiabetic rabbits at 9 and 12 months. (a) and (b)
∗P <. 05 compared with baseline; (c) and (d)
∗P <. 05
between diabetic and age-matched nondiabetic animals.
3.6. Renal Dysfunction. Plasma levels of blood urea nitrogen
(BUN)andcreatinineincreasedfollowingdiabetesinduction
(Figures 1(c) and 1(d)). There were signiﬁcant diﬀerences
between the diabetic and age-matched nondiabetic rabbits at
9months(P< . 0001forBUNandP = .0008forcreatinine)
and 12 months (P = .0002 for BUN and P< . 0001 for
creatinine).
3.7. Hyperlipidemia. Plasma cholesterol and triglyceride lev-
elsincreasedinalldiabeticrabbits.Thereweresigniﬁcantdif-
ferences between the diabetic and age-matched nondiabetic
rabbits at 9 months (P< . 0001 for cholesterol and P<
.0001 for triglyceride) and 12 months (P< . 0001 for choles-
terol and P< . 0001 for triglyceride, Figures 2(a) and 2(b)).
3.8. Plasma Enzymes Levels. The majority of the plasma
levels of ALT, AST, CK, and LDH were within normal range;
however levels were elevated at times in individual rabbits.
In addition, plasma total protein was within normal range
although proteinuria was observed (Table 1).
3.9. Ketoacidosis and Urine Ketosis. Diabetic ketoacidosis
was demonstrated by increased blood beta-hydroxybutyrate
(BHBA) [13] .W h e np e a kb l o o dg l u c o s el e v e l sw e r ea b o v e
500mg/dl, BHBA levels at times increased to more than
10mg/dl or even greater than 40mg/dl (ketoacidosis)
(Figure 3). Ketones were also present in the urine of some
severely diabetic rabbits whose peak blood glucose levels
were greater than 500mg/dl.
3.10. Wound Healing. In rabbits wounded at two weeks
following the induction of diabetes, wound closure time
tended to be longer (16.5 ± 3.5 days) than the age-matched
nondiabetic rabbits (15.6 ± 1.1 days), but the diﬀerenceExperimental Diabetes Research 5
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Figure 2: Hyperlipidemia: there were statistically signiﬁcant diﬀerences in plasma cholesterol (a) and triglyceride (b) levels between the
diabetic and age-matched nondiabetic rabbits at 9 and 12 months.
∗P <. 0001 between the diabetic and age-matched nondiabetic rabbits.
Table 1: Changes of several serum biochemical measurements over 12 months in diabetic rabbits.
Index Baseline 3 months 6 months 9 month 12 months
ALT (u/l) 16 ± 12 33 ± 16 28 ± 20 31 ± 17 26 ± 10
AST (u/l) 12 ± 62 4 ± 13 45 ± 30
∗ 31 ± 18 25 ± 9
LDH (u/l) 48 ± 36 47 ± 26 65 ± 45 52 ± 26 78 ± 33
CK (u/l) 456 ± 140 494 ± 120 406 ± 193 465 ± 383 398 ± 279
TP (g/dl) 5.7 ± 1.55 .4 ± 1.66 .9 ± 1.95 .6 ± 1.06 .3 ± 1.3
ALT: alanine aminotransferase, AST: aspartate aminotransferase, LDH: lactate dehydrogenase, CK: creatine kinase, TP: total protein.
∗P <. 05 versus Baseline.
was not statistically signiﬁcant (P = .3865). However, in
rabbits that had been diabetic for one year, wound closure
time (19.7 ± 3.7 days) was signiﬁcantly longer than in age-
matched nondiabetic rabbits (15.1 ± 1.0 days) (P< . 01,
Figure 4).
3.11. Other Complications. Throughout the study some
animals exhibited anorexia, severe weight loss, ptyalism,
weakness, and lethargy. These were caused by excessive
hyper- or hypoglycemia, and all of them were treated by
adjusting insulin dosages. Four rabbits suﬀered from slight
anemia, with hemoglobin between 7–9g/dl. The animals
were not treated for anemia since it was not severe.
3.12. Pathologic Changes. Histopathologic changes in ani-
mals that had diabetes for one year are shown in Figure 5.
The pancreas showed marked beta-cell damage and thick-
ened arterial walls. The kidney showed hyaline arterioloscle-
rosis. The amorphous, homogeneous eosinophilic material
is seen in the thickened vascular wall of aﬀerent glomerular
arteriole and the lumen is narrowed markedly (arrow).
Glomerular atrophy is also present. In the liver, there was
lipidaccumulationinthecytoplasmofthehepatocyteswhich
appeared as vacuoles (hepatic fatty degeneration). The aortic
media demonstrated mild spot calciﬁcations in small areas.
4. Discussion
To our knowledge, this is by far the largest group of diabetic
rabbits kept for one year or longer for scientiﬁc research. A
long-term diabetic animal model has many potential bene-
ﬁts. Our experience has shown that, with careful manage-
ment, alloxan-induced diabetic rabbits can be kept for one
year or longer in reasonably good health. The biochemical
and histological changes indicated well-developed diabetes.
Many studies have been conducted in diabetic rabbits
over short periods of time in the past several decades.
However, short-term diabetic rabbits have severely limited
the diabetic research capabilities because human diabetes
lasts for decades and many diabetic complications take years
t od e v e l o p .AP u b M e ds e a r c hr e v e a l e do n l yaf e wr e p o r t si n
which diabetic rabbits were kept alive for 3–6 months for
pharmacology or growth factor studies [14–18]. Only one
article was found in which 3 rabbits were kept for 12 months
to study the aortic intima-media of alloxan-diabetic rabbits
[19]. Due to many medical complications, the management6 Experimental Diabetes Research
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Figure 3: The relationship between blood beta-hydroxybutyrate
(BHBA) and blood glucose concentrations. When the glucose
levels increased above 500mg/dl, the BHBA levels increased up
to10mg/dl (increase in ketone bodies) or greater than 40mg/dl
(ketoacidosis).
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Figure 4: There were signiﬁcant diﬀerences in closure times
between one-year diabetic and age-matched nondiabetic wounds
(P< . 01). Healing times in 2-week diabetic rabbits were longer
than the age-matched nondiabetic rabbits, however the diﬀerence
was not statistically signiﬁcant (P = .3865).
of long-term diabetic rabbits is labor intensive, expensive,
and technically demanding which reduces the incentive to
perform these studies over long periods of time.
The toxin-induced diabetic rabbits were ﬁrst adminis-
trated alloxan by Dunn and Mcletchie [20] who by studying
the crush syndrome in rabbits investigated the eﬀects of a
seriesofuricacidderivativesincludingalloxanwithregardto
kidney damage. The animals which received alloxan became
comatose after 12 hours, and were hypothermic with high
blood urea and low blood glucose values. Shortly after the
injection there was a marked hyperglycemia. Histological
examination revealed early signs of expected kidney damage.
An unexpected ﬁnding was a partial or total necrosis of
the pancreatic islets. Other tissues showed no damage, and
alloxan was gradually adopted to generate diabetes in ani-
mals. Over the course of our study, alloxan-induced diabetic
animals exhibited classic symptoms of human diabetes, such
as hyperglycemia, glucosuria, polydipsia, and polyuria, loss
of body weight despite polyphagia, hyperlipemia, ketonuria,
and acidosis.
Following the administration of alloxan there is a
characteristic response in blood glucose level [4]. In the ﬁrst
2 hours, blood glucose rises. This transient hyperglycemia
is thought to be due to sudden glycogen breakdown in the
liver [21]. The reason for the breakdown of liver glycogen
during this phase is unknown, but may be a secondary eﬀect
of epinephrine release. The second phase is a hypoglycemic
phase which may be severe enough to lead to death if it is not
prevented or treated with supplemental glucose [4, 22]. The
hypoglycemia is due to a sudden outpouring of insulin from
dying beta cells [21]. The hypoglycemia generally appears
after 6 hours [23]. Hypoglycemia is more pronounced in
fasted animals [24].
The susceptibility to both toxic and diabetogenic doses
of alloxan varies widely not only in diﬀerent species but also
among animals of the same species [25, 26]. The range of
the safe diabetogenic dose of alloxan in a particular animal
is quite narrow and even light overdosing may be toxic and
result in death. This loss is likely due to kidney tubular cell
necrotic toxicity, in particular when high doses of alloxan are
administered [27]. The dose of alloxan (100mg/kg) utilized
inthisstudyisdiabetogenicandlesstoxic.However,thisdose
does not necessarily produce stable diabetes in rabbits [28].
Sixty percent of the rabbits in this study required a second
dose of alloxan to maintain persistent hyperglycemia, and all
of these animals survived until the end of the experiment.
The recovery from diabetes has been proposed to be the
consequence of either a multiplication of beta cells that
survive the initial alloxan injection or the formation of new
beta-cells from the duct epithelium of the exocrine portion
of pancreas [29, 30]. Another possible explanation is that
there may have been a stress-induced hyperglycemia at the
time of the initial alloxan injection initiated by handling
of the animals. It has been shown that hyperglycemia can
provide protection against alloxan-induced injury [31]. It
has also been shown that male rabbits are more likely to
experience stress-induced hyperglycemia than female rabbits
[32] and this may have contributed to the high percentage
of rabbits requiring a second dose of alloxan. In future
studies we plan to measure the blood glucose level of the
rabbits immediately prior to the administration of alloxan
to be able to better predict those animals that may require
a second dose of alloxan as well as increase the amount
of handling that they receive during the acclimation period
in an attempt to decrease the percentage of rabbits that
require a second dose. Since untreated diabetics have higher
complication rates than regulated diabetics, we chose to treat
the rabbits in this study with insulin to increase the survival
time of the rabbits, but we did not fully regulate the diabetes.
Normal blood glucose levels were maintained a mean of 8
hours per day, and a hyperglycemic state was maintained
for a mean of 16 hours per day. Therefore this model mayExperimental Diabetes Research 7
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Figure 5: The pathological changes of a 12-month diabetic rabbit. (a) and (b) There is marked damage to beta-cells (arrow); (c) and (d)
the microscopic cross-section of the artery in the pancreas shows a thickened vessel wall (arrow); (e) and (f) Hyaline arteriolosclerosis.
The amorphous, homogeneous eosinophilic material is seen in the thickened vascular wall of aﬀerent glomerular arteriole and the lumen
is narrowed markedly (arrow). Glomerular atrophy is also present; (g) and (h) lipid accumulation in the cytoplasm of the hepatocytes
appearing as vacuoles (hepatic fatty degeneration); (i) and (j) the microscopic section of the aortic media showing mild spot calciﬁcations
(arrow).8 Experimental Diabetes Research
more closely represent a model of poorly regulated diabetes
because glucose ﬂuctuation has been shown to cause more
tissue damage than stable hyperglycemia [33].
Based on the severity of hyperglycemia, we divided the
rabbits into three groups, those that had mild, moderately
severe, and severe diabetes. Each group exhibited certain
characteristic physiologic changes throughout the course of
the study. In the mild diabetic group, body weights increased
rather quickly, the biochemical values were usually in the
normal range, the animals BG returned to levels <300mg/dl
and they required a second injection of alloxan. In the
severediabeticgroup,bodyweightsincreasedveryslowlyand
biochemical values were mostly abnormal including elevated
BUN, anemia due to renal dysfunction [34], dyslipidemia
[35], and at times ketoacidosis [36]. In the moderately severe
diabetic group, the changes observed were a combination of
the above two groups and their blood glucose levels were
more manageable.
In addition to hyperglycemia in the long-term diabetic
rabbits, we observed other characteristics of diabetes. While
all of the rabbits in this study gained body weight, the gain in
thediabeticrabbitswaslessthanthegainobservedintheage-
matched animals. Prior to alloxan administration, their body
weights ranged from 2.0 to 2.5kg. After one year, they only
increased to 3.5–4.0kg, a weight comparable to a normal
4-5-month old rabbit. However, the body weight of age-
matched nondiabetic rabbits in this study increased to more
than5.0kgafteroneyearwhichisconsistentwiththenormal
growth rate provided by the vendor. The increase in body
weight in this study, albeit small, appeared to be diﬀerent
from many of the previous studies in which diabetic rabbits
lose weight. A large number of previous studies utilized
rabbits that were 3-4 months of age and were considered to
be young adults. Our ﬁnding of an increase in body weight
is similar to that reported by Goseki et al. [16] who utilized
young rabbits that were 10 weeks of age similar to those
used in our study. Because body weight change is a reﬂection
of whole body function, maintenance of appropriate body
weight might be an important factor for the rabbits to
survive long-term in the diabetic state. Plasma cholesterol
and triglyceride levels increased in all diabetic rabbits in
this study. These ﬁndings are in agreement with previously
published studies [35]. We also found a few diabetic animals
that suﬀered from anemia. These rabbits all had poor renal
function, which is similar to clinical human patients due
to a decrease in erythropoietin production by the damaged
kidneys [37].
The histological changes observed in animals kept for
one year were typical of diabetic damage. In addition
to pancreatic islet damage, microscopic cross-sections of
the pancreatic arteries showed thickening of vessel walls
which indicates atherosclerosis in this organ. In the aorta,
microscopic sections of the aortic media demonstrated mild
spot calciﬁcations in small areas which are also indicative of
atherosclerosis. Similar changes were also seen in the kidney,
in which the aﬀerent glomerular arteriole wall was markedly
thickened and the lumen was narrowed. Glomerular atrophy
was also present in the kidney. In the liver, lipid accumulated
in the cytoplasm of the hepatocytes as vacuoles. All of these
histological changes are consistent with those seen in long-
term diabetics which may not be present in animals that are
diabetic for shorter periods of time.
One of the most common complications of human
diabetes is ulceration of the extremities, which has been
subjected to numerous experimental studies. However, all
of these studies suﬀer from several limitations that make it
diﬃcult to extrapolate animal results to clinical settings. One
is the time during which the animal has been diabetic, and
anotheristheetiologyofdiabeticulcers.Itiswellknownthat
human diabetic ulcers are the result of years, even decades
of diabetes mellitus. Neuropathy, vasculopathy, immune
dysfunction, and biochemical abnormalities all contribute
to the development of chronic wounds in diabetic patients
[38,39].Todate,noneoftheanimalmodelsusedfordiabetic
wound research have all of the same features of human
diabetic wounds with the exception of hyperglycemia. The
length of time that rabbits have been maintained in a
hyperglycemic state in the majority of rabbit wound healing
studies has been very limited, with the shortest being several
days and the longest being two months. These short periods
of persistent hyperglycemia simply cannot reproduce the
changesobservedinhumandiabetes.Inordertotestwhether
the time of hyperglycemia had any eﬀect on wound healing,
we compared wound healing times in diabetic rabbits and
age-matched nondiabetic animals at two weeks and one
year. To date little is known about the diﬀerence between
wound healing in short-term hyperglycemia and long-term
diabetes [8]. In the present study, short-term hyperglycemia
(2 weeks) appeared to delay the healing process to a degree
as compared to nondiabetic rabbits, but this diﬀerence was
not statistically signiﬁcant. However, in the one-year diabetic
rabbits, the closure time of wounds was signiﬁcantly longer
than age-matched nondiabetic wounds. Our results appear
to indicate that wound healing time is proportionate to the
lengthofdiabetictimes.Astateofsystemichyperglycemia,as
seen in diabetes, may inﬂuence wound closure in numerous
ways.Severalhypotheseshavebeendescribedintheliterature
such as the formation of glycation end products [40],
hyperosmolarity[41],andalteredinsulinsignalinginvarious
ways [42]. However, hyperglycemia alone plays a limited
role in the status of many nonhealing chronic wounds,
while other pathophysiological changes take much longer to
develop. If a rabbit’s life span is 5–8 years, one year may
be comparable to 15–20 years of human life, although such
an approximation is an oversimpliﬁcation. The biochemical
and histological changes found in this study provide some
evidencetomimichumandiabeticchanges;ananimalmodel
that is diabetic for a longer period of time than that which is
more commonly published provides more features closer to
human diabetic changes.
In summary, with careful management which includes
adaptive and repeated injections of alloxan, accurate adjust-
ment of insulin dose, monitoring body weight and bio-
chemical values, performing blood glucose curves, and
adjusting insulin dosage as soon as animals exhibit abnormal
symptoms, alloxan-induced diabetic rabbits can be kept for
one year or longer in reasonably good health. Such a model
may prove useful in scientiﬁc research on diabetes.Experimental Diabetes Research 9
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